Insightful and Reliable Valuations Across the Full Spectrum of Healthcare and Life Sciences
In the current, fast-changing healthcare and life sciences environment, participants are presented with an unprecedented number of growth opportunities. However, given the highly regulated nature of these industries, participants must also mitigate enterprise and reputational risk.
Ankura has a specialized valuation and transaction advisory team attuned to the unique considerations of the healthcare and life sciences industries. Our professionals provide a full range of valuation and transaction advisory services to help our clients pursue growth while navigating a dynamic regulatory and business environment. Clients leverage our insightful and thorough analyses to enable informed business decisions concerning M&A, regulatory compliance, tax compliance, divestitures, joint ventures, financial reporting, litigation support, compensation, and other critical motivations.
Ankura’s valuation professionals assist healthcare provider and payer clients with the fair market valuation and fairness opinions related to a wide variety of businesses, assets, ownership interests, and services. Our valuation opinions often focus on:
Ankura’s valuation professionals assist life sciences clients with the fair market valuation of a broad array of products and services for regulatory compliance, including:
We offer compensation valuation services based on in-depth data analytics and rigorous methodologies specifically designed to address the complexities of FMV under healthcare regulations, including the Stark Law and the Anti-Kickback Statute.
We provide valuations to assist our clients in meeting financial reporting requirements. We are well-versed in fair value analyses related to business combinations under ASC 805 and impairment testing as required by ASC 350.
Hospital Joint Venture
Ankura was engaged to provide a fair market valuation analysis of a joint venture entity that included five general acute care hospitals with over 1,750 licensed beds and various outpatient facilities for transaction planning purposes. Ankura’s valuation was used to determine the relative equity value split for the joint venture parties.
Our professionals have valued hundreds of business enterprises, equity interests, strategic alliances, as well as tangible and intangible assets that often must withstand third-party scrutiny. Ankura’s valuation experts have decades of experience in the healthcare and life sciences industry and are attuned to the unique legal and regulatory issues affecting valuations. In addition, our team has testified in both federal and state cases, as well as arbitration settings, when disputes arise related to the value of healthcare and life sciences businesses, assets, and arrangements.